Companies in #Myotonic Dystrophy Type 1 (DM1)
Found 1 company operating in this sector.
Avidity Biosciences is a biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™) designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapeutics to target previously untreatable genetic muscle disorders. Founded in 2012 and headquartered in San Diego, California, Avidity was acquired by Novartis AG in early 2026 for approximately $12 billion to strengthen Novartis' late-stage neuroscience and RNA medicines pipeline. In late 2026, following a $1.9 billion impairment charge recorded by parent company Novartis on lead Phase 3 myotonic dystrophy type 1 (DM1) candidate del-desiran (AOC 1001), Avidity filed a California WARN Act notice eliminating 40 positions (~8% of workforce) across clinical operations, medical writing, and regulatory affairs on a rolling basis beginning December 31, 2026.